Verification evidence is still being completed.
PDF / print export
ClexBio AS
Oslo, Norway
- Verified lead
- Armend G. Hati
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- Regenerative Medicine, Tissue Engineering, and CLEX Hydrogel Scaffold Technology
- Review cycle
- 24 April 2026
- Full address
- Gaustadalleen 21, 0349 Oslo, Norway (operational lab at Oslo Science Park)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- ClexBio team page listing Armend G. Hati as Chief Executive Officer and Co-founder.
- Editorial note
- Oslo regenerative-medicine startup with named co-founder CEO, EQT Foundation backing, and a CSEM bioreactor partnership targeting Type-1 diabetes and vascularized tissue implants.
Regenerative Medicine, Tissue Engineering, and CLEX Hydrogel Scaffold Technology
Public co-founder CEO disclosure, EQT Foundation investment record, CSEM bioreactor partnership
Oslo regenerative-medicine startup with named co-founder CEO, EQT Foundation backing, and a CSEM bioreactor partnership targeting Type-1 diabetes and vascularized tissue implants.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Oslo regenerative-medicine startup with named co-founder CEO, EQT Foundation backing, and a CSEM bioreactor partnership targeting Type-1 diabetes and vascularized tissue implants.
- Lead
- Armend G. Hati (verified ↗)
- Address
- Gaustadalleen 21, 0349 Oslo, Norway (operational lab at Oslo Science Park) (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Pre-clinical tissue engineering
- Capabilities
- Microscale Hydrogel Scaffold Fabrication · Vascularized Tissue Construct Generation · CSEM Bioreactor Partnership
- Founded
- 2020
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Armend G. Hati
Chief Executive Officer and Co-Founder
Full addressGaustadalleen 21, 0349 Oslo, Norway (operational lab at Oslo Science Park)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
ClexBio imprint page with registered address and operational laboratory at Oslo Science Park.
Open sourcePre-clinical tissue engineering
Oslo, Norway. Regenerative Medicine, Tissue Engineering, and CLEX Hydrogel Scaffold Technology. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and EMA for future clinical development
Public co-founder CEO disclosure, EQT Foundation investment record, CSEM bioreactor partnership
Regenerative Medicine, Tissue Engineering, and CLEX Hydrogel Scaffold Technology
Oslo regenerative-medicine startup with named co-founder CEO, EQT Foundation backing, and a CSEM bioreactor partnership targeting Type-1 diabetes and vascularized tissue implants.
Editorial note
ClexBio (legal entity Nordovo Biosciences AS) operates from Oslo Science Park with a named co-founder CEO, EQT Foundation investment, and a CSEM bioreactor partnership, focused on vascularized engineered tissue implants.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Microscale Hydrogel Scaffold Fabrication
Vascularized Tissue Construct Generation
CSEM Bioreactor Partnership
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
CLEX hydrogel scaffold fabrication
Decellularization and ECM production
Vascularized tissue construct workflows
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is ClexBio AS located?
- ClexBio AS operates from Gaustadalleen 21, 0349 Oslo, Norway (operational lab at Oslo Science Park), Oslo, Norway.
- Who runs ClexBio AS?
- ClexBio AS is led by Armend G. Hati, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does ClexBio AS do?
- Oslo regenerative-medicine startup with named co-founder CEO, EQT Foundation backing, and a CSEM bioreactor partnership targeting Type-1 diabetes and vascularized tissue implants. Core capabilities: Microscale Hydrogel Scaffold Fabrication, Vascularized Tissue Construct Generation, CSEM Bioreactor Partnership.
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.